ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors

June 2-6, 2017; Chicago, Illinois
Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.
Format: Microsoft PowerPoint (.ppt)
File Size: 878 KB
Released: June 9, 2017


Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Related Content

Clinical commentary with Shannon N. Westin, MD, MPH, discussing patients’ considerations affecting treatment choices, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Released: September 23, 2021

Podcast episode with expert insights on practice changing data from virtual IGCS 2021 for endometrial, ovarian, cervical cancers, from Clinical Care Options (CCO)

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: September 21, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.